Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics

Annals of Pharmacotherapy

Volumn 41, Issue 10, 2007, Pages 1593-1603

  Citrome, Leslie L ^a,b   Holt, Richard I G ^c   Zachry, Woodie M ^d,e   Clewell, Jerry D ^d,e   Orth, Paul A ^d   Karagianis, Jamie L ^d,f   Hoffmann, Vicki Poole ^d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e ABBOTT LABORATORIES   (United States)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Antipsychotic; Diabetes; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DATA BASE; DIABETES MELLITUS; DIET; FAMILY HISTORY; HUMAN; INCIDENCE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCINFO; RISK ASSESSMENT;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 34748881146     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K141     Document Type: Article

References (58)

1. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
2. Lorenz WF. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 1922;8:184-96.
3. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
4. Citrome L. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today 2004;40:445-64.
5. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
7. Racoosin JA, Feeney J, Burkhart G, Boehm G. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004;27:2088-9.
8. Etminan M. Pharmacoepidemiology II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004;24:1105-9.
9. Etminan M, Samii A. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs. Pharmacotherapy 2004;24:964-9.
10. Barner JC, Worchel J, Yang M. Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among central Texas veterans. Pharmacotherapy 2004;24:1529-38.
11. Leslie DL, Rosenheck R. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709-11.
12. Ostbye T, Curtis LH, Masselink LE, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2005;14:407-15.
13. Sacchetti E, Turrina C, Parrinello G, et al. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol 2005;20:33-7.
14. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-70.
15. Feldman PD, Hay LK, Kennedy JS, et al. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in geriatric population in the United States. J Am Med Dir Assoc 2004;5:38-46.
16. Miller EA, Leslie DL, Rosenheck RA. Incidence of new onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193:387-95.
17. Moisan J, Gregoire JP, Gaudet M, et al. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf 2005;14:427-36.
18. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 2004;6:5. www.medscape.com/viewarticle/466800 (accessed 2006 Nov 3).
19. Zhao Z, Tunis SL, Loosbrock DL. Risk of diabetes for individuals with schizophrenia treated with antipsychotics. J Applied Res 2002;3:287-95.
20. Caro J, Ward A, Levington C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135-9.
21. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003;23:1411-5.
22. Farwell WR, Stump TE, Wang J, et al. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 2004;19:1200-5.
23. Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-43.
24. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-30.
25. Gianfrancesco F, Grogg A, Mahmoud R, et al. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003;25:1150-71.
26. Gianfrancesco F, White R, Wang R, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-35.
27. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims based approach. Arch Gen Psychiatry 2001;58:1172-6.
28. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243-8.
29. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002;63:758-62.
30. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-13.
31. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 2005;14:417-25.
32. Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002;22:236-43.
33. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
34. Lee DW, Fowler RB, Kadlubek PJ, et al. No significant difference in diabetes risk during treatment with typical versus atypical antipsychotics: results from a large observational study. Behavioral Health Trends 2002; 14(Nov):46-52.
35. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37:1849-57. DOI 10.1345/aph.1D142
36. Grill V, Persson G, Carlsson S, et al. Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetic subjects. Diabetologia 1999; 42:15-23.
37. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care 2006;29: 1585-90.
38. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
39. Millar WJ, Young TK. Tracking diabetes: prevalence, incidence and risk factors. Health Rep (Statistics Canada, Cat 82-003) 2003;14(3):35-47.
40. Geiss LS, Pan L, Cadwell B, et al. Changes in incidence of diabetes in US adults, 1997-2003. Am J Prev Med 2006;30:371-7.
41. Canadian Diabetes Association, Clinical Practice Guidelines Expert Committee. CDA 2003 clinical practice guidelines for the prevention and management of diabetes: screening and prevention. Can J Diabetes 2003;27(suppl 2):S10-3.
42. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90.
43. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-23.
44. Citrome L, Stroup TS. Schizophrenia, clinical antipsychotic trials of intervention effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60:933-40.
45. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
46. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22.
47. Koller EA, Schneider B, Bennett K, et al. Clozapine-associated diabetes mellitus. Am J Med 2001;111:716-23.
48. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-52.
49. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23: 735-44.
50. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-63.
51. Hedenmalm K, Haag S, Stahal M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25:1107-16.
52. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk of initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
53. Wright AD, Barber SG, Kendall MJ, et al. Beta-adrenoreceptor-blocking drugs and blood sugar control in diabetes mellitus. BMJ 1979;1:159-61.
54. Citrome L, Jaffe A, Levine J, et al. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr Serv 2006;57:1132-9.
55. Ammon HP, Orci L, Steinke J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther 1973;187:423-9.
56. Engl J, Laimer M, Niederwanger A, et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005;10:1089-96.
57. Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol 2006;26:504-7.
58. Beckley ET. New ADA initiative moves beyond 'metabolic syndrome.' DOC News 2006;3(July 1):1.